ImmunoGen | Target a Better Now | ADC Technology-Focused Cancer Treatment

Target a

better Now

Targeting a better life for people with cancer is why we get up in the morning. It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life.

Watch Our Story

Meet Nick

After being diagnosed with a rare and aggressive blood cancer called BPDCN, Nick learned that nothing’s promised in this life.

Watch Nick’s Story

Meet Gayle

Meet Gayle. A fiercely independent, sharp-witted wife, mother, and proud grandmother who has effectively beat acute myeloid leukemia (AML).

Watch Gayle’s Story


Antibody-drug conjugates, or ADCs, are a targeted way to treat cancer.

For 40 years, ImmunoGen has been researching and developing ADCs designed to disrupt the progression of cancer. Because we believe life deserves fewer interruptions and more good days.

learn more

40 years ago, ImmunoGen began as an idea

Baruj Benacerraf, head of the Sidney Farber Cancer Institute (now the Dana Farber Cancer Institute), was approached by a small group of investors with a vision: to create more effective, better tolerated anti-cancer therapies. Specifically, they wanted to find a way to leverage the targeting ability of antibodies to deliver toxic drug directly to cancer cells. Benacerraf went on to suggest that the investors start with a grant from which the Institute would work with dedicated scientists.

The rest, they say, is our history…

learn more